These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17826491)

  • 41. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
    Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
    Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
    Loeb S; Roehl KA; Yu X; Han M; Catalona WJ
    Urology; 2007 Jan; 69(1):108-12. PubMed ID: 17270629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
    D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
    J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methods of calculating prostate-specific antigen velocity.
    Connolly D; Black A; Murray LJ; Napolitano G; Gavin A; Keane PF
    Eur Urol; 2007 Oct; 52(4):1044-50. PubMed ID: 17197071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
    Loeb S; Roehl KA; Catalona WJ; Nadler RB
    BJU Int; 2008 Apr; 101(7):817-21. PubMed ID: 18321315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
    D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
    Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
    Daskivich TJ; Regan MM; Oh WK
    Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does PSA velocity predict prostate cancer in pre-screened populations?
    Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
    Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival.
    Cheung R; Tucker SL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):20-4. PubMed ID: 16814948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
    Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
    Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen velocity in healthy Korean men with initial PSA levels of 4.0 ng/mL or less.
    Ham WS; Kang DR; Kim YS; Seong do H; Kim SJ; Cheon SH; Cho IR; Cho JS; Kim CI; Choi YD
    Urology; 2008 Jul; 72(1):99-103. PubMed ID: 18533237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage radiation in men after prostate-specific antigen failure and the risk of death.
    Cotter SE; Chen MH; Moul JW; Lee WR; Koontz BF; Anscher MS; Robertson CN; Walther PJ; Polascik TJ; D'Amico AV
    Cancer; 2011 Sep; 117(17):3925-32. PubMed ID: 21437885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.